Compare ADM & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADM | ALNY |
|---|---|---|
| Founded | 1902 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6B | 38.9B |
| IPO Year | 2008 | 2004 |
| Metric | ADM | ALNY |
|---|---|---|
| Price | $84.55 | $264.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 28 |
| Target Price | $64.00 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 3.3M | 1.6M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | 2.49 | ★ 2.71 |
| Revenue | ★ $80,269,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $4.80 | $52.67 |
| Revenue Next Year | $2.77 | $31.48 |
| P/E Ratio | ★ $33.51 | $96.79 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $55.58 | $197.81 |
| 52 Week High | $88.46 | $495.55 |
| Indicator | ADM | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 59.85 |
| Support Level | $76.16 | $197.81 |
| Resistance Level | $84.10 | $314.04 |
| Average True Range (ATR) | 2.78 | 10.36 |
| MACD | 0.50 | 5.45 |
| Stochastic Oscillator | 73.95 | 81.94 |
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.